G1SecL05: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Moazzam Khan (talk | contribs) No edit summary |
|||
| Line 12: | Line 12: | ||
[[Image:LYMErix.jpg|center|thumb|Retail Packaging of LYMErix]] | [[Image:LYMErix.jpg|center|thumb|Retail Packaging of LYMErix]] | ||
Vaccine efficiency was evaluated by immunizing mice with LYMErix and using ELISA to measure their serum antibody response to ospA. In clinical trials conducted in highly endemic areas of the United States with sample size exceeding 10,000 subjects, LYMErix was found to confer protective immunity to ''B. burgdorferi'' in 76% of adults and 100% of children with only mild and transient short term effects. | Vaccine efficiency was evaluated by immunizing mice with LYMErix and using ELISA to measure their serum antibody response to ospA. In 1996, clinical trials conducted in highly endemic areas of the United States with sample size exceeding 10,000 subjects, LYMErix was found to confer protective immunity to ''B. burgdorferi'' in 76% of adults and 100% of children with only mild and transient short term effects. | ||
==Development of the recombinant vaccine== | ==Development of the recombinant vaccine== | ||
